Company Overview and News
DAVAO CITY — An additional power supply of about 3,000 megawatts (MW) is projected to be required by the Mindanao grid by 2030, according to Mindanao Development Authority (MinDA) Assistant Secretary Romeo M. Montenegro.
ABZPF NG ABTZY ABZPY NGGTF AEV NGG AP
SPC Power Corp. has turned over the 153.1-megawatt (MW) gas turbine power plant in Naga, Cebu to the Power Sector Assets Liabilities Management, Inc. (PSALM), ending the legal tussle over the ownership of the asset.
ABZPF ABZPY SPC AP
Next week, the Energy Policy Development Program (EPDP), a USAID-funded project implemented by the UP Economics Foundation, will have its last lecture and the launch of a book that incorporates conferences, lectures, and seminars the program has sponsored over the last four years.
FSGCF FGENG ABZPF FGENF FGEN FSGCY ABZPY AP
Investing in utility stocks has been traditionally regarded as a classic defensive strategy, especially in times of market volatility, because utilities are relatively more stable than nonutility stocks.
ABZPF MWC ABZPY SPC AP
ZAMBOANGA CITY — Financially troubled Zamboanga City Electric Cooperative, Inc. (Zamcelco) is aiming to finally award an investment management contract (IMC) by Aug. 2 after two bidders submitted letters of intent.
ABZPF MER ABZPY AP
FIGHTING COAL Residents of Atimonan town, Quezon, and members of the group Power for People rally on Ortigas Avenue on June 5 to protest the continued construction of another coal power plant in Quezon province.—NIÑO JESUS ORBETA
ABZPF MER ABZPY AP
FOR STABLE SUPPLY President Duterte (center) joins officials of Aboitiz Power and TeaM Energy at the inauguration of the 420-megawatt Pagbilao 3 power plant in Quezon province on Thursday. Seated with Mr. Duterte are (front row, from left) Jera Co. Inc. Senior vice president Toshiro Kodama, Energy Secretary Alfonso Cusi, Aboitiz Power chair Erramon Aboitiz; and Marubeni Corp. senior executive officer Yasuo Hirota.
ABZPF ABZPY MARUF AP
PAGBILAO, Quezon — Aboitiz Power Corp. and TeaM Energy Corp. have formally launched on Thursday the 420-megawatt (MW) coal-fired power plant in Pagbilao, Quezon that is expected to boost electricity supply in Luzon.
ABZPF ABZPY AP
Last May 18, BusinessWorld, the most read and most respected business newspaper in the Philippines, triumphantly staged the third edition of its annual BusinessWorld Economic Forum in the Grand Ballroom of Grand Hyatt Manila, in Bonifacio Global City, Taguig City.
MER GTCAP GTCXY SVTMF SMCP1 ABZPY BDOUY SM BDOUF SMGBF SMIVY SMC PNX3B PNXP PNX3A MPCFF PNX UBNC MPCIY SMGBY ABZPF BDO SMC2B SMC2A SMC2D SMC2C MPI SMC2F SMC2E AP LTG
A unit of the Manila Electric Co. is now considering to look for a new contractor to build a planned 600-megawatt power plant at the Redondo Peninsula in Zambales as the previous contractor had proposed a new contract that would make the project nonviable.
ABZPF MER ABZPY AP
Last week, May 22, a BusinessWorld report said “DoE forecast for peak power demand exceeded on May 17” referring to 10,688 MW peak demand in the Luzon grid on May 17 reported by the National Grid Corp. of the Philippines (NGCP) vs peak demand in 2017 of 10,054 MW.
ABZPF NG ABZPY NGGTF NGG AP
ABOITIZ Power Corp. is targeting to increase its contracted capacity to contestable customers by at least 100 megawatts (MW) this year as it looks to target electricity users with consumption of at least 750 kilowatts, its president said.
ABZPF ABZPY AP
43m - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
22h - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET